JLE

Epileptic Disorders

MENU

Epidiolex-induced skin rash Volume 22, numéro 4, August 2020

  • [Błaszczyk et al., 2015] Błaszczyk B., Lasoń W., Czuczwar S.J. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015;67:426-434. 3
  • [Devinsky et al., 2016] Devinsky O., March E., Friedman D. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270-278. 3
  • [Devinsky et al., 2018] Devinsky O., Patel A., Thiele E. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204-e1211.
  • [Epidolex®, 2019] Epidolex® (Cannabidiol) Oral Solution (Prescribing Information). Carlsbad, CA: Greenwich Biosciences, Inc., 2019.
  • [Fowler et al., 2019] Fowler T., Bansal A., Lozsadi D. Risks and management of antiepileptic drug-induced skin reactions in the adult outpatient setting. Seizure. 2019;72:61-70.
  • [Kelso, 2014] Kelso J.M. Potential food allergens in medications. J Allergy Clin Immunol. 2014;133:1509-1518. 6
  • [Krauss, 2006] Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr. 2006;6:33-37. 2
  • [Onfi®, 2018] Onfi® (Clobazam) (Prescribing Information). Deerfield, IL: Lundbeck, Inc., 2018.
  • [Thiele et al., 2018] Thiele E.A., Marsh E.D., French J.A. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085-1096. 10125
  • [Tohyama and Hashimoto, 2011] Tohyama M., Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol. 2011;38:222-228.
  • [Sekar and Pack, 2019] Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Res 2019; 8: F1000 Faculty Rev-234.